Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase

Journal of Virology

Volumn 86, Issue 13, 2012, Pages 7268-7279

  Bouvier, Nicole M ^a   Rahmat, Saad ^a   Pica, Natalie ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLYCINE; HISTIDINE; OSELTAMIVIR; SIALIDASE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; ENZYME ASSAY; FEMALE; GENE PRODUCT; GUINEA PIG; HUMAN; HUMAN CELL; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVERSE GENETICS; SEASONAL INFLUENZA; STRAIN DIFFERENCE; VIROGENESIS; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; FEMALE; GUINEA PIGS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEURAMINIDASE; NEW YORK; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; REVERSE GENETICS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS;

CAVIA; MAMMALIA;

EID: 84864117825     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07242-12     Document Type: Article

References (58)

1. Baz M, Abed Y, Boivin G. 2007. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 74:159-162.
2. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. 2010. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J. Infect. Dis. 201:740-745.
3. Belser JA, et al. 2012. Influenza virus respiratory infection and transmission following ocular inoculation in ferrets. PLoS Pathog. 8:e1002569. doi:10.1371/journal/ppat.1002569.
4. Belser JA, Maines TR, Tumpey TM, Katz JM. 9 December 2010, posting date. Influenza A virus transmission: contributing factors and clinical implications. Expert Rev. Mol. Med. 12:e39. http://dx.di.org/10/1017 /S146233994100001705.
5. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
6. Bouvier NM, Lowen AC. 2010. Animal models for influenza virus pathogenesis and transmission. Viruses 2:1530-1563.
7. Bouvier NM, Lowen AC, Palese P. 2008. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J. Virol. 82:10052-10058.
8. Carrat F, et al. 2008. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am. J. Epidemiol. 167:775-785.
9. Casalegno JS, et al. 2010. Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009. Antiviral Res. 87:242-248.
10. Centers for Disease Control and Prevention. 2009. 2008-2009 influenza season week 14 ending April 11, 2009. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/flu/weekly/weeklyarchives2008 -2009/weekly14.htm.
11. Centers for Disease Control and Prevention. 2008. Influenza activity- United States and worldwide, 2007-08 season. MMWR Morb. Mortal. Wkly. Rep. 57:692-697.
12. Chao DL, Bloom JD, Kochin BF, Antia R, Longini IM, Jr. 2012. The global spread of drug-resistant influenza. J. R Soc. Interface 9:648-656.
13. Chou YY, et al. 2011. The M segment of the 2009 new pandemic H1N1 influenza virus is critical for its high transmission efficiency in the guinea pig model. J. Virol. 85:11235-11241.
14. Collins PJ, et al. 2009. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27:6317-6323.
15. Collins PJ, et al. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258-1261.
16. Duan S, et al. 2010. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 6:e1001022. doi:10.1371/journal/ppat.1001022.
17. Fodor E, et al. 1999. Rescue of influenza A virus from recombinant DNA. J. Virol. 73:9679-9682.
18. Hamelin ME, et al. 2011. Reduced airborne transmission of oseltamivirresistant pandemic A/H1N1 virus in ferrets. Antivir. Ther. 16:775-779.
19. Hay AJ, et al. 2008. Report, WHO Influenza Centre, London: characteristics of human influenza AH1N1, AH3N2, and B viruses isolated September 2007 to February 2008. World Health Organization, Geneva, Switzerland. http://www.nimr.mrc.ac.uk/documents/about/interim_report _mar_2008.pdf.
20. Herlocher ML, et al. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
21. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146:2275-2289.
22. Huang Y, et al. 2011. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza A infection. PLoS Genet. 7:e1002234. doi:10.1371/journal.pgen.1002234.
23. Hurt A. 13 March 2007, posting date. Fluorometric neuraminidase inhibition assay, standard operating procedure WHO-025. Neuraminidase Inhibitor Surveillance Network, London, United Kingdom. http://www.nisn.org/documents/A.Hurt_Protocol_for_NA_fluorescence.pdf.
24. Itoh Y, et al. 2009. In vitro and in vivo characterization of new swineorigin H1N1 influenza viruses. Nature 460:1021-1025.
25. Ives JA, et al. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55:307-317.
26. Jayaraman A, et al. 2011. A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets. PLoS One 6:e17616. doi:10.1371/ journal.pone.0017616.
27. Killingley B, et al. 2012. Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. J. Infect. Dis. 205:35-43.
28. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. 2009. Use of oseltamivir in 12 European countries between 2002 and 2007: lack of association with the appearance of oseltamivir-resistant influenzaA(H1N1)viruses. Euro Surveill. 14:pii=19112. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-19112.
29. Lakdawala SS, et al. 2011. Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus. PLoS Pathog. 7:e1002443. doi:10.1371/ journal.ppat.1002443.
30. Lindemann J, et al. 2004. A numerical simulation of intranasal air temperature during inspiration. Laryngoscope 114:1037-1041.
31. Lowen AC, Mubareka S, Steel J, Palese P. 2007. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 3:1470-1476.
32. Lowen AC, Mubareka S, Tumpey TM, Garcia-Sastre A, Palese P. 2006. The guinea pig as a transmission model for human influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 103:9988-9992.
33. Maher JA, DeStefano J. 2004. The ferret: an animal model to study influenza virus. Lab. Anim. (NY) 33:50-53.
34. Maines TR, et al. 2009. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325:484-487.
35. Matrosovich M, Matrosovich T, Garten W, Klenk HD. 2006. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3:63.
36. Meijer A, et al. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
37. Munster VJ, et al. 2009. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325:481-483.
38. Neumann G, et al. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. U. S. A. 96:9345-9350.
39. Palese P, Shaw ML. 2007. Orthomyxoviridae: the viruses and their replication, p 1647-1678. In Knipe DM, Howley PM (ed), Fields virology, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
40. Patrozou E, Mermel LA. 2009. Does influenza transmission occur from asymptomatic infection or prior to symptom onset? Public Health Rep. 124:193-196.
41. Pearce MB, et al. 2012. Pathogenesis and transmission of swine origin A(H3N2)v influenza viruses in ferrets. Proc. Natl. Acad. Sci. U. S. A. 109: 3944-3949.
42. Pica N, Chou YY, Bouvier NM, Palese P. 2012. Transmission of influenza B viruses in the guinea pig. J. Virol. 86:4279-4287.
43. Pleschka S, et al. 1996. A plasmid-based reverse genetics system for influenza A virus. J. Virol. 70:4188-4192.
44. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
45. Rameix-Welti MA, et al. 2006. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob. Agents Chemother. 50:3809-3815.
46. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4:e1000103. doi:10.1371/journal.ppat.1000103.
47. Seibert CW, et al. 2010. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 84:11219-11226.
48. Seibert CW, Rahmat S, Krammer F, Palese P, Bouvier NM. 2012. Efficient transmission of pandemic H1N1 influenza viruses with highlevel oseltamivir resistance. J. Virol. 86:5386-5389.
49. Steel J, Lowen AC, Mubareka S, Palese P. 2009. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog. 5:e1000252. doi:10.1371/journal.ppat.1000252.
50. Wagner R, Matrosovich M, Klenk HD. 2002. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12:159-166.
51. Wang S, et al. 2008. Simplified recombinational approach for influenza A virus reverse genetics. J. Virol. Methods 151:74-78.
52. World Health Organization. 2008. Influenza A(H1N1) virus resistance to oseltamivir: last quarter 2007 to 5 May 2008. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/influenza/H1N1 ResistanceWeb20080505.pdf.
53. World Health Organization. 2008. Influenza A(H1N1) virus resistance to oseltamivir: last quarter 2007 to 5 May 2008. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/influenza/H1N1 ResistanceWeb20080505.pdf.
54. World Health Organization. 2009. Table 2 seasonal influenza A(H1N1) virus resistant to oseltamivir, last quarter 2008 to 31 March 2009. World Health Organization, Geneva, Switzerland. http://www.who.int/csr /disease/influenza/2008-9NHemiResistanceTable2.pdf.
55. World Health Organization 15 February 2008, posting date. WHO/ ECDC frequently asked questions for oseltamivir resistance. World Health Organization, Geneva, Switzerland. http://www.who.int/csr /disease/influenza/oseltamivir_faqs/en/index.html#whatis.
56. Yang JR, et al. 2011. Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005-2009. PLoS One 6:e18177. doi:10.1371/journal. pone.0018177.
57. Yen HL, et al. 2007. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81:12418-12426.
58. Zaraket H, et al. 2010. Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses. J. Clin. Microbiol. 48:1085-1092.